Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Amgen to acquire Dezima Pharma for up to $1.55 billion: $300 million cash at closing and up to $1.25 billion in development and sales milestones for the…
Amgen agrees to buy Dutch firm Dezima Pharma in a deal worth up to $1.55bn; TA-8995 reduced LDL-C by 45-48% versus baseline in a Phase 2b dyslipidemia trial,…
Characterizes obicetrapib as Amgen's CETP castoff, noting Amgen walked away in 2017 amid class-wide CETP failures before NewAmsterdam revived the asset with…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Amgen acquired Netherlands-based Dezima Pharma for $300M upfront with up to $1.25B in milestones plus royalties, adding TA-8995 (obicetrapib), an oral CETP inhibitor showing 45-48% LDL-C reduction in Phase 2b. Amgen discontinued the program ~2017; rights later reacquired by NewAmsterdam Pharma.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Amgen Inc. / Dezima Pharma B.V. (this deal) | 2015 | $1.6B | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| Amgen Inc. / Otezla (from Celgene/BMS) | 2019 | $13.4B | 68 |
← Browse all deals · How we score deals
More: 2015 deals · Amgen Inc. deals · Cardiovascular deals